Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

"Given the huge obesity and diabetes epidemics in the U.S., access to GLP-1 medications is a public health priority," Emanuel said in a statement. "Their potential is only realized if patients can ...

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...